NVNO

enVVeno is a development-stage medical-device company with effectively no product revenue — the only revenue in the dataset is a stale $31.2K from FY2019, and management states plainly it is 'not currently generating revenue' and doesn't expect any 'until we successfully commercialize our lead product candidate after receiving FDA approval, if ever.' Every meaningful ratio here (233x P/S, +597% gross margin, -66,892% operating margin) is an artifact of a near-zero denominator and carries no signal. This is a pre-commercial biotech-style bet, not an operating business, and it must be judged on its pipeline and its balance sheet, both of which are compromised.

The pipeline just took a decisive hit: on August 19, 2025 the FDA issued a not-approvable letter for the VenoValve, the company's original first-in-class surgical product. The entire thesis now rests on a single, earlier-stage successor — the enVVe transcatheter valve — which has only 'completed pre-clinical testing' and whose pivotal trial the company 'expects to begin in 2026.' Approval is years and multiple binary catalysts away, in a novel indication where management concedes 'there are currently no devices approved as surgical or non-surgical replacement venous valves' — i.e., no regulatory precedent to derisk the path.